Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.9K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.9K
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

7.5K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
7.5K
The Periodic Table and Organismal Elements00:57

The Periodic Table and Organismal Elements

205.8K
OverviewElements are the smallest units of matter that cannot be broken down further by chemical processes. There are 118 known elements, but not all of these are naturally-occurring, and fewer still are essential for life. Living matter is composed primarily of carbon, nitrogen, hydrogen, and oxygen, with smaller amounts of other elements like calcium, phosphorus, potassium, and sulfur. Other elements are also necessary for life but only in trace amounts.The Periodic Table Provides Information...
205.8K
Erythropoiesis01:14

Erythropoiesis

6.8K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
6.8K
Microbes and Other Elemental Cycles01:24

Microbes and Other Elemental Cycles

66
Microbial activity plays a pivotal role in the biogeochemical cycling of iron and manganese, especially at the redox gradients characteristic of stratified aquatic environments. These cycles are driven by microbial transformations between oxidized and reduced forms of the metals, allowing organisms to exploit them for metabolic energy and structural purposes.Iron Cycling Across Redox GradientsIn neutral, oxygen-rich surface waters, iron is predominantly found in its oxidized, insoluble ferric...
66
The Early Endosome: Endocytosis of Transferrin01:28

The Early Endosome: Endocytosis of Transferrin

5.2K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
5.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study.

NPJ precision oncology·2026
Same author

Cardiovascular Trials in Hemodialysis: Closing the Evidence Gap.

Journal of the American College of Cardiology·2026
Same author

Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes.

European journal of heart failure·2025
Same author

Effects of Ferric Derisomaltose in Heart Failure with Iron Deficiency according to Renal Function in the IRONMAN Randomised Controlled Trial.

American journal of nephrology·2025
Same author

Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher- versus lower-dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial.

European journal of heart failure·2025
Same author

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials.

European journal of heart failure·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 4, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.7K

鉄欠乏性貧血

Anthony Lopez1, Patrice Cacoub2, Iain C Macdougall3

  • 1Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.

Lancet (London, England)
|August 29, 2015
PubMed
まとめ
この要約は機械生成です。

鉄欠乏性貧血は 世界人口の3分の"に及ぶもので 母親と子供の健康に影響を及ぼします 最近の診断方法や 静脈注射鉄の治療は この広範囲に広がる病気の 安全で効果的な治療法を提供しています

さらに関連する動画

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

5.7K
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.6K

関連する実験動画

Last Updated: Apr 4, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.7K
Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

5.7K
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.6K

科学分野:

  • 血液学
  • 公衆衛生
  • 栄養学

背景:

  • 鉄欠乏性貧血 (IDA) は,世界の人口の約3分の1に影響を及ぼす世界的な健康問題です.
  • 小児 (0~5歳),妊婦,妊婦などの脆弱なグループに不均衡な影響を及ぼします.
  • IDAは,慢性腎臓病,心不全,癌,炎症性腸疾患などの慢性疾患としばしば併発する.

研究 の 目的:

  • 鉄欠乏性貧血の総合的な概要を提示する.
  • 現在の診断方法,治療戦略,将来の研究方向について議論する.

主な方法:

  • IDAの臨床表現,流行病学,および病理生理学のレビュー
  • 血清フェリチンとトランスファーリン飽和度を含む様々なバイオマーカーの診断精度の評価
  • 経口鉄,静脈内鉄,ヘプシジンベースの治療法を含む,現在および新興の治療法の評価.

主要な成果:

  • 血清フェリチンとトランスファーリン飽和度などの高度な診断マーカーは,IDA診断の伝統的な赤血球指数よりも高い精度を提供します.
  • 静脈内での鉄分配合は 鉄分を補うための安全で効果的な代替手段です
  • ヘプシディンは,診断と治療の応用が可能な鉄の恒常性の重要な調節剤として浮上しています.

結論:

  • 鉄欠乏性貧血は,多面的な管理戦略を必要とする重大な世界的な健康問題です.
  • 先進的なバイオマーカーによる正確な診断と 現代の鉄製剤による効果的な治療は不可欠です
  • ヘプシディンの役割に関するさらなる研究は,IDAのための新しい治療目標を解き明かすことができます.